ImmPACT Bio Overview
ImmPACT Bio is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company's logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to prevent antigen escape, prevent "on-target off-tumor" toxicities, and overcome the immunosuppressive tumor microenvironment. The company's technology is based on the work of Yvonne Chen, PhD, and Antoni Ribas, MD, PhD, both from University of California, Los Angeles, and Gideon Gross, PhD, from the MIGAL-Galilee Research Institute.
Cumulative Funding Raised Over Time ($)
$18.0MAug 2020
$129.0MJan 2022
$129.0MJul 2016
$129.0MJun 2019
Latest News
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
growth-positive
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Lyell Immunopharma, Inc. announced its acquisition of ImmPACT Bio USA Inc., a clinical-stage biotechnology company. This acquisition strengthens Lyells clinical pipeline by adding ImmPACTs dual-targeting CD19/CD20 CAR T-cell product candidate, IMPT-314, designed for hematologic malignancies. The transaction involves $30 million in cash and 37.5 million shares of Lyell common stock, with additional contingent shares based on clinical milestones. Lyell plans to focus on next-generation CAR T-cell therapies, discontinuing some earlier-stage programs. The acquisition is expected to enhance Lyells capabilities in developing durable cancer therapies, with a pivotal trial for IMPT-314 anticipated in 2025. The deal is expected to close in the fourth quarter of 2024.
Acquisition
growth-positive
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus | BioSpace
ImmPACT Bio USA INC. has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its ongoing Phase 1b/2 study evaluating IMPT-514 for the treatment of refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE). IMPT-514 is a potentially first-in-class CD19/CD20 bispecific CAR T-cell therapy designed for deep and extensive depletion of autoreactive immune cells. Initial efficacy and safety data from the trial is expected in the second half of 2024.
Investment
growth-positive
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
ImmPACT Bio USA, Inc. has appointed Biren Amin, M.B.A., to its board of directors. Amin brings decades of experience in capital markets, finance, and corporate strategy. His expertise will be valuable as the company continues to build and advance its pipeline of next-generation CAR T-cell therapies for cancer treatment. ImmPACT Bio is rapidly advancing its novel bispecific CAR to treat aggressive B-cell lymphoma into Phase 1/2 clinical trials. Amins knowledge of finance and capital markets will help implement strategies to grow the company and move its therapies through clinical trials. ImmPACT Bio aims to develop transformative oncology medicines for cancer patients in need of new treatment options.
Management Changes
growth-positive
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
ImmPACT Bio has received clearance from the FDA for its first Investigational New Drug (IND) application for IMPT-314, a bispecific CAR T-cell therapy targeting B-cell lymphomas. The company plans to initiate a Phase 1/2 clinical trial in early 2023. The therapy has shown promising results in an investigator-led study, with 70% of patients achieving a complete response. ImmPACT Bio raised $111 million in a Series B financing round to support its cell therapy development and manufacturing facilities. The company is also investigating CAR T-cell technologies for solid tumors.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $137M |
| Last funding | $8M |
| Stage | Acquired |
| Rounds | 5 |
| Investors | 10 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | immpact-bio.com/ |
| Careers | Careers page |
Locations
Rehovot, Israel
8501 Fallbrook Ave, West Hills, CA 91304, USA
Photos & Videos
No files yet
ImmPACT Bio Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (11)
biotechnologybiopharmaceuticallife-sciencesgenetic-engineeringmedical-technologiescancer-therapyhospitalshealthcare-providersoncologycell-therapycancerImmPACT Bio Financials
$137M
Total funding
Undisclosed
Capital raised
$8M
Last funding
Acquired
Funding stage
5
Total rounds
10
Investors
Cumulative Funding Raised Over Time ($)
$18.0MAug 2020
$129.0MJan 2022
$129.0MJul 2016
$129.0MJun 2019
Private Equity Funding
B Round
Jan 2022
$111M
venBio (Lead)
,
OrbiMed, Novartis Venture Fund, RMGP Biopharma Investment Fund, Decheng Capital, Bukwang Pharmaceutical , Foresite Capital, Surveyor Capital
A Round
Aug 2020
$18M
Takeda Ventures, RMGP Biopharma Investment Fund, OrbiMed, Bukwang Pharmaceutical
Seed
Jun 2019
Undisclosed
OrbiMed, Novartis Venture Fund, RMGP Biopharma Investment Fund
Undisclosed Round
Jul 2016
Undisclosed
FutuRx
Non-Equity Funding
GrantEvent
Feb 2024
$8M
California Institute for Regenerative Medicine (CIRM) (Lead)
Public Offering / Exit
MNAEvent
Oct 2024
Undisclosed
Mergers & Acquisitions
MNAEvent
Jul 2021
Undisclosed
ImmPACT Bio Lifecycle
Cumulative Funding Raised Over Time
$18.0MAug 2020
$129.0MJan 2022
$129.0MJul 2016
$129.0MJun 2019
All Events
B Round
Jan 2022
$111M
venBio (Lead)
,
OrbiMed, Novartis Venture Fund, RMGP Biopharma Investment Fund, Decheng Capital, Bukwang Pharmaceutical , Foresite Capital, Surveyor Capital
A Round
Aug 2020
$18M
Takeda Ventures, RMGP Biopharma Investment Fund, OrbiMed, Bukwang Pharmaceutical
Seed
Jun 2019
Undisclosed
OrbiMed, Novartis Venture Fund, RMGP Biopharma Investment Fund
Undisclosed Round
Jul 2016
Undisclosed
FutuRx
GrantEvent
Feb 2024
$8M
California Institute for Regenerative Medicine (CIRM) (Lead)
MNAEvent
Oct 2024
Undisclosed
MNAEvent
Jul 2021
Undisclosed
ImmPACT Bio News
10 articlesLyell Immunopharma Completes Acquisition of ImmPACT Bio
growth-positive
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Lyell Immunopharma, Inc. announced its acquisition of ImmPACT Bio USA Inc., a clinical-stage biotechnology company. This acquisition strengthens Lyells clinical pipeline by adding ImmPACTs dual-targeting CD19/CD20 CAR T-cell product candidate, IMPT-314, designed for hematologic malignancies. The transaction involves $30 million in cash and 37.5 million shares of Lyell common stock, with additional contingent shares based on clinical milestones. Lyell plans to focus on next-generation CAR T-cell therapies, discontinuing some earlier-stage programs. The acquisition is expected to enhance Lyells capabilities in developing durable cancer therapies, with a pivotal trial for IMPT-314 anticipated in 2025. The deal is expected to close in the fourth quarter of 2024.
Acquisition
growth-positive
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus | BioSpace
ImmPACT Bio USA INC. has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its ongoing Phase 1b/2 study evaluating IMPT-514 for the treatment of refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE). IMPT-514 is a potentially first-in-class CD19/CD20 bispecific CAR T-cell therapy designed for deep and extensive depletion of autoreactive immune cells. Initial efficacy and safety data from the trial is expected in the second half of 2024.
Investment
growth-positive
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
ImmPACT Bio USA, Inc. has appointed Biren Amin, M.B.A., to its board of directors. Amin brings decades of experience in capital markets, finance, and corporate strategy. His expertise will be valuable as the company continues to build and advance its pipeline of next-generation CAR T-cell therapies for cancer treatment. ImmPACT Bio is rapidly advancing its novel bispecific CAR to treat aggressive B-cell lymphoma into Phase 1/2 clinical trials. Amins knowledge of finance and capital markets will help implement strategies to grow the company and move its therapies through clinical trials. ImmPACT Bio aims to develop transformative oncology medicines for cancer patients in need of new treatment options.
Management Changes
growth-positive
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
ImmPACT Bio has received clearance from the FDA for its first Investigational New Drug (IND) application for IMPT-314, a bispecific CAR T-cell therapy targeting B-cell lymphomas. The company plans to initiate a Phase 1/2 clinical trial in early 2023. The therapy has shown promising results in an investigator-led study, with 70% of patients achieving a complete response. ImmPACT Bio raised $111 million in a Series B financing round to support its cell therapy development and manufacturing facilities. The company is also investigating CAR T-cell technologies for solid tumors.
Investment
growth-positive
ImmPACT Bio Names Jonathan Benjamin, M.D., Ph.D. as Chief Medical Officer
ImmPACT Bio has appointed Jonathan Benjamin, M.D., Ph.D. as its chief medical officer. Dr. Benjamin brings extensive experience in clinical research and development in the biopharmaceutical space, as well as clinical practice expertise as a hematologist-oncologist. He will lead ImmPACT Bios clinical development strategy. The appointment is expected to have a positive impact on the companys growth. ImmPACT Bio is a clinical-stage company focused on developing transformative CAR T-cell therapies for cancer patients. Their technology aims to address key challenges in cancer treatment by preventing antigen escape, toxicities, and overcoming the immunosuppressive tumor microenvironment.
Management Changes
growth-positive
ImmPACT Bio Names Sylvain Roy as Chief Technology Officer BioSpace
ImmPACT Bio has appointed Sylvain Roy as chief technology officer. Roy will oversee technical operations and product quality across the company. He brings over two decades of experience in cell and gene therapy, global technical operations, and leading high-performing teams. ImmPACT Bio is a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer. Roys appointment is expected to contribute to the advancement of the companys pipeline of next-generation CAR T-cell therapies.
Management Changes
growth-positive
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
ImmPACT Bio has closed $111 million in Series B financing led by venBio Partners, Foresite Capital, and Decheng Capital. The company also announced the appointment of Sheila Gujrathi as chair of its board of directors and Sumant Ramachandra as president and CEO. ImmPACT Bio provided an update on its Phase 1 clinical study for its CD19-CD20 bi-specific CAR T therapy, reporting positive results with seven out of eight patients achieving complete remission. The companys logic-gate based CAR T platforms address key challenges in cancer treatment. The financing will be used to further develop these platforms. The investors in the financing round include venBio Partners, Foresite Capital, Decheng Capital, Surveyor Capital, OrbiMed, Novartis Venture Fund, RM Global Partners, and Bukwang Pharmaceutical.
InvestmentManagement Changes
growth-positive
ImmPACT Bio Announces Completion of Merger with Kalthera to Progress Next-Generation CAR T Therapies for the Treatment of Cancer
ImmPACT Bio USA, Inc. has announced its merger with Kalthera, Inc., a biotechnology company. Kalthera is currently progressing a clinical trial at UCLA with a bispecific CAR T-cell immunotherapy candidate. The merger will help ImmPACT Bio move forward as a clinical-stage company and bring them closer to delivering new cancer therapies. ImmPACT Bio is backed by multiple investors including OrbiMed and Novartis Venture Fund.
Acquisition
growth-positive
ImmPACT Bio USA Raises $18M In Series A Financing
ImmPACT Bio USA, a company developing novel cell therapies for treating cancer, has raised $18 million in a Series A equity financing round. The funding included investments from OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., RM Global Partners (RMGP) BioPharma Investment Fund, Novartis Venture Fund, Bukwang Pharmaceutical, Hayan Health Networks, Inc., and JVC Investment Partners. ImmPACT Bio USA is focused on developing engineered T-cell therapeutics that target loss of genes in solid tumors.
Investment
ImmPACT Bio Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 49 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
ImmPACT Bio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515549004 |
| Crunchbase | immpact-bio-usa |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-08-07T00:00:00.000Z |
| Created | 2018-04-17T00:00:00.000Z |
| Status detail | Acquired by Lyell Immunopharma on Oct, 2024 |